Get to know our clinical trials
Clinical trial to evaluate the efficacy of treatments by controlling minimal residual disease in a population with early breast cancer.
THE MAIN OBJECTIVE IS TO EVALUATE THE EFFICACY, IN TERMS OF THE PERCENTAGE OF PATIENTS WITH A 90% REDUCTION OR ELIMINATION OF BASELINE CTDNA AFTER THREE MONTHS, OF THE DIFFERENT GROUPS.
Technical Summary
- PRELIMINARY EFFICACY STUDY TO EVALUATE THE EFFECTIVENESS OF TREATMENTS BY MONITORING MINIMAL RESIDUAL DISEASE WITH CTDNA IN A POPULATION WITH EARLY-STAGE RH-POSITIVE/HER2-NEGATIVE BREAST CANCER.
- Code EudraCT: 2022-002616-24
- Protocol number: MEDOPP485
- Promoter: Medica Scientia Innovation Research SL
- Molecule/Drug: Giredestrant / Abemaciclib/ Inavolisib
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.